TenNor Therapeutics (Suzhou) Limited (SEHK: 6872)
Health Care · Biotechnology · CN
HK$199.10
+0.71% today · -5.6% 1Y
TenNor Therapeutics (Suzhou) Limited (SEHK: 6872) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.31B and employs 5 people.
Over the last twelve months the share price has lost 5.6%, trading between 145.00 and 287.00.
6872 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.31B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.85
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- HK$287.00
- 52-week low
- HK$145.00
- Avg volume (3M)
- —
- Shares outstanding
- 51.75M
- Employees
- 5
- Next earnings
- —
About TenNor Therapeutics (Suzhou) Limited
TenNor Therapeutics (Suzhou) Limited specializes in researching, developing, and bringing to market unique therapies for illnesses arising from bacterial infections and bacterial metabolic functions. Its robust product pipeline includes Rifasutenizole (TNP-2198), designed to combat Helicobacter pylori infections. Another key asset, Rifaquizinone (TNP-2092), is being advanced in an injectable formulation to treat Periprosthetic Joint Infection (PJI), Acute Bacterial Skin and Skin Structure Infections (ABSSSI), and infections associated with Left Ventricular Assist Devices (LVADs). An oral variant of TNP-2092 is aimed at addressing conditions linked to gut bacterial metabolism, such as Hepatic Encephalopathy (HE) and Irritable Bowel Syndrome with Diarrhea (IBS-D). Furthermore, their development programs feature a topical TNP-2092 for confronting drug-resistant bacterial strains and biofilm-mediated infections; TNBi-1, a novel narrow-spectrum small molecule for H. pylori; TNBi-2, a broad-spectrum, multi-targeting small molecule for Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD); and TNBm-1, a broad-spectrum bifunctional small molecule for metabolic disorders. The company was established in 2012 and maintains its headquarters in Suzhou, China.
- ISIN
- CNE100007KG6
- Founded
- 2012
- Listed since
- May 22, 2026
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.09 | -0.46% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.